Loading
A phase 1/2 trial of Oral DNA Vaccine in triple-negative breast cancer, run by NEC Bio B.V, now recruiting.
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer is a phase 1/2 interventional study registered as NCT06631092 by NEC Bio B.V, with 28 participants planned, started 2024-11-20 and due to reach its primary completion in 2027-12-31. Interventions recorded: Oral DNA Vaccine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PD-1, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Early triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares PD-1 and the tag pipeline.
Shares PD-1 and the tag pipeline.
Shares PD-1 and the tag pipeline.
Shares PD-1 and the tag pipeline.
Shares Early triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/